secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2026-08-12T20:05:37+00:00
Accession:  0001104659-26-094862
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q2 revenue up 23% to $18.5M; net loss narrows to $0.3M
----------------------------------------------------------------------

- Total revenues $18.5M for Q2 2026, +23% from $15.0M in Q2 2025; Emrosi sales $8.1M.
- GAAP net loss narrowed to $0.3M ($0.01/sh) from $3.8M ($0.16/sh) year ago.
- Non-GAAP EBITDA and Adjusted EBITDA positive for both three and six months ended June 30, 2026.
- Cash $25.6M at June 30, 2026 vs $24.1M at Dec 31, 2025; SG&A down $1.0M to $10.9M.
- Emrosi total prescriptions ~36,000 in Q2 2026, up from ~30,000 in Q1 and ~27,000 in Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/0001104659-26-094862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465926094862/tm2622742d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-094862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer